三阴性乳腺癌的影像学特征与雄激素受体状态的关系
本研究为单中心临床试验的子研究,前瞻性监测144例I-III期三阴性乳腺癌患者接受新辅助全身治疗的反应,按免疫组化雄激素受体状态分组,由两名乳腺放射科医生盲法回顾分析乳腺X线、超声和MRI图像。结果显示雄激素受体阳性三阴性乳腺癌与乳腺X线不均匀致密型乳腺构成、肿块伴钙化、乳腺X线不规则肿块形状及超声不规则肿块形状相关;多因素分析中雄激素受体阳性与乳腺X线不均匀致密型乳腺构成、高肿块密度及超声不规则肿块形状独立相关。
要点
- 雄激素受体阳性三阴性乳腺癌在乳腺X线上更常见不均匀致密型乳腺构成(多因素p=0.01)和高肿块密度(p=0.003)。
- 超声上不规则肿块形状与雄激素受体阳性三阴性乳腺癌独立相关(多因素p=0.0004)。
- 多模态乳腺影像可能有助于识别对化疗相对耐药的腔面雄激素受体亚型三阴性乳腺癌。
核心结论
- 三阴性乳腺癌的影像学特征因雄激素受体状态而异,多模态乳腺影像可能有助于识别对化疗相对耐药的腔面雄激素受体亚型。
研究设计与样本
- 单中心临床试验的子研究,前瞻性监测I-III期三阴性乳腺癌患者接受新辅助全身治疗的反应,本次中期影像分析纳入144例已知免疫组化雄激素受体状态的患者(雄激素受体阳性定义为至少10%肿瘤细胞核染色阳性),两名乳腺放射科医生盲法回顾性阅片并按第五版乳腺影像报告和数据系统词典共识描述索引病灶(乳腺X线、超声和乳腺磁共振成像),采用逻辑回归分析。
关键影像表现/征象
- 乳腺X线显示不均匀致密型乳腺构成与雄激素受体阳性三阴性乳腺癌相关(单因素p=0.02,多因素p=0.01)。
- 乳腺X线显示肿块伴钙化与雄激素受体阳性三阴性乳腺癌相关(单因素p=0.05)。
- 乳腺X线显示不规则肿块形状与雄激素受体阳性三阴性乳腺癌相关(单因素p=0.03)。
- 超声显示不规则肿块形状与雄激素受体阳性三阴性乳腺癌相关(单因素p=0.003,多因素p=0.0004)。
- 乳腺X线显示高肿块密度与雄激素受体阳性三阴性乳腺癌独立相关(多因素p=0.003)。
诊断标准与关键数值
- 雄激素受体阳性定义为至少10%肿瘤细胞核雄激素受体染色阳性。
- 影像特征按第五版乳腺影像报告和数据系统词典描述。
- p≤0.05认为有统计学意义。
临床应用与阅片要点
- 阅片时可关注乳腺X线不均匀致密型乳腺构成、高肿块密度及超声不规则肿块形状等与雄激素受体阳性三阴性乳腺癌相关的影像特征。
- 多模态乳腺影像(乳腺X线、超声和乳腺磁共振成像)可能有助于识别腔面雄激素受体亚型三阴性乳腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Different molecular subtypes of triple-negative breast cancer (TNBC) have previously been identified through analysis of gene expression profiles. The luminal androgen receptor (LAR) subtype has been shown to have a lower rate of pathologic complete response to neoadjuvant chemotherapy than other TNBC subtypes. The purpose of this study was to determine if the imaging features of TNBCs differ by AR (androgen receptor) status, which is a surrogate immunohistochemical (IHC) marker for the chemoresistant LAR subtype of TNBC.
MATERIALS AND METHODS: This sub-study was part of a clinical trial in patients with stage I-III TNBC who were prospectively monitored for response while receiving neoadjuvant systemic therapy (NAST) at a single comprehensive cancer center. This interim imaging analysis included 144 patients with known AR status measured by IHC. AR-positive (AR+) tumors were defined as those in which at least 10% of tumor cells had positive nuclear AR staining. Two experienced, fellowship-trained breast radiologists who were blinded to the IHC results retrospectively reviewed and reached consensus on all imaging studies for the index lesion (i.e., mammogram, ultrasound, and breast magnetic resonance imaging). The index lesion for each patient was reviewed and described according to the fifth edition of the Breast Imaging Reporting and Data System lexicon. Logistic regression modeling was used to identify imaging features predictive of AR status. p ≤ 0.05 was considered statistically significant.
RESULTS: Univariate logistic regression models for AR status showed that AR+ TNBC was significantly associated with heterogeneously dense breast composition on mammography (p = 0.02), mass with calcifications (p = 0.05), irregular mass shape on mammography (p = 0.03), and irregular mass shape on sonography (p = 0.003). Multivariate logistic regression models for AR status showed that AR+ TNBC was significantly associated with heterogeneously dense breast composition on mammography (p = 0.01), high mass density on mammography (p = 0.003), and irregular mass shape on sonography (p = 0.0004).
CONCLUSION: The imaging features of TNBCs differ by AR status. Multimodality breast imaging may help identify the LAR subtype of TNBC, which has been shown to be a subtype that is relatively resistant to neoadjuvant chemotherapy.
引用
- Candelaria RP, Adrada BE, Wei W, et al. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019. PMID: 31005169. doi:10.1016/j.ejrad.2019.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。